Research on a CoviVac vaccine for children could be completed by the end of 2022. More than a thousand people aged 3 to 17 will take part in the trials. Konstantin Chernov, Development Director of the Federal Scientific Center for Research and Development of Immunobiological Preparations named after Chumakov, told Izvestia about this.
“One of the directions of the third phase of research on our CoviVac vaccine for children involves studying how it works on volunteers aged three to seventeen who have been ill for more than six months and have not yet encountered the virus. The children will be divided into three age groups, and the research will be carried out gradually with a decrease in the age threshold. We will not immediately address the youngest. Initially, it will be a group of teenagers aged 17-12, the second category – from 12 to 6 years old, and only then from 6 to 3 years old,” he said.
The study of the drug for teenagers aged 12 to 17 is expected to be completed in the summer. In case of successful trials, it will be registered and approved for use in this age group. Until the end of the year, tests will continue among children from 3 to 6 and from 6 to 12 years old.
The fact that the Ministry of Health allowed the third phase of clinical trials of the CoviVac vaccine with the participation of children became known on February 7.
Read the details in Konstantin Chernov’s interview with Izvestia:
“The inactivated vaccine is one of the safest”
Source: IZ
Jane Stock is a technology author, who has written for 24 Hours World. She writes about the latest in technology news and trends, and is always on the lookout for new and innovative ways to improve his audience’s experience.
